The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Seachange in Mexico on Cannabis Could Benefit This Small Cap

Contributed Opinion
  ()
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. read more >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

  ()
Shares of Iovance Biotherapeutics traded 12% higher after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. read more >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

  ()
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. read more >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance

  ()
Aquestive Therapeutics Inc. shares traded 20% higher after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. read more >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

  ()
Shares of RedHill Biopharma Ltd. traded higher after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. read more >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership

  ()
Shares of BeiGene Ltd. traded 35% higher to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. read more >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

  ()
Shares of IVERIC bio traded 100% higher after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. read more >

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'

Research Report
  ()
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. read more >
News Update

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases

News Update
  ()
These therapeutic candidates add to those already in the firm's pipeline. read more >

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

  ()
Shares of Biogen Inc. soared after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings. read more >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

Research Report
  ()
The details of this study and a second one are outlined in a ROTH Capital Partners report. read more >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

  ()
Dermira shares traded higher after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. read more >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

  ()
Shares of Protalix Biotherapeutics skyrocketed on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. read more >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer

  ()
Shares of Achillion Pharmaceuticals traded much higher after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. read more >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

  ()
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. read more >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

  ()
Shares of Relmada Therapeutics traded wildly after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100200% higher and the stock was halted several times trading due to extreme price volatility. read more >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

  ()
Shares of Cerecor Inc. traded higher after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. read more >

Technical Analyst Expects Health Technologies Firm to Break Higher

Contributed Opinion
  ()
Technical analyst Clive Maund outlines the reasons this stock might break higher. read more >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

  ()
Shares of Reata Pharmaceuticals traded 12% higher after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. read more >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

  ()
Shares of Ra Pharmaceuticals doubled after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. read more >
News Update

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial

News Update
  ()
Data from this study should be released by the end of this year. read more >

Coverage Initiated on U.S.-Based Precision Therapy Developer

Research Report
  ()
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. read more >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%

  ()
Akcea Therapeutics' shares rose 30% on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. read more >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

  ()
PDS Biotechnology Corp. shares traded 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. read more >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

  ()
Shares of Dova Pharmaceuticals rose 38% on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. read more >
Showing Results: 26 to 50 of 125 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts